J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.
New label shows Cosentyx is superior to J&J’s rival in long-term.
Siliq will be cheaper than rivals from Novartis and Eli Lilly.
Pharma begins early intervention trial after Cosentyx shows “disease modifying” properties
Decision paves way for cheaper competitor in autumn 2018.
Guselkumab can also be used if older drug Stellara fails.
But drug will have boxed warning over suicidal ideation.
Celgene continues with focus on autoimmune diseases.
But patents could delay launch for more than a year.
